FDA Approves Axonics' Recharge-Free Sacral Neuromodulation System

The FDA has approved Axonics Inc's AXNX recharge-free sacral neuromodulation (SNM) implantable neurostimulator (INS).

  • The Axonics F15 recharge-free SNM system's functional life has been validated for over 15 years at typical stimulation parameters and more than 2 decades at lower energy settings.
  • INS volume: 10 cubic centimeters (20% smaller than the market's other non-rechargeable SNM device).
  • Constant current automatically adjusts stimulation output.
  • Related: US Patent Office Rejects Three More Axonics' Challenge To Medtronic Patents.
  • MRI compatibility: 1.5T and 3.0T whole-body scanners.
  • Patient remote control: intuitive, recharge-free key fob featuring SmartMRI technology.
  • A proprietary algorithm recommends optimal stimulation parameters based on intraoperative responses.
  • The company expects to begin shipping the Axonics F15 system in April.
  • Price Action: AXNX shares closed 3.42% higher at $56.00 during after-hours trading on Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsHealth CareFDAGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!